Intercellular cell adhesion molecule-1 (ICAM-1) is a cell-surface glycoprotein capable of eliciting bidirectional signals that activate signalling pathways in leukocytes, endothelial, and smooth muscle cells. Gene transfer of xenogeneic ICAM-1 into EL-4 lymphomas causes complete tumor rejection; however, it is unknown whether the mechanism responsible involves the ''foreignness'' of the ICAM-1 transgene, bidirectional signalling events, ICAM-1-receptor interaction, or a combination of the latter. To begin to address this question, we constructed four different therapeutic expression vectors encoding full-length ICAM-1, and forms in which the Nterminal ligand-binding domains and cytoplasmic tail had been deleted. Mouse EL-4 tumors (0.5 cm in diameter), which actively suppress the immune response, were significantly inhibited in their growth following injection of expression plasmids encoding either full-length xenogenic (human) ICAM-1, or a functional cytoplasmic domain-deficient form that retains ligand-binding activity. Efficacy of ICAM-1-mediated antitumor immunity was significantly augmented by administration of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA), which suppressed blood supply to the tumor, leading to enhanced leukocyte infiltration, and complete tumor eradication in a gene dosage and CD8 + T cell and NK cell-dependent fashion. Generation of potent cytotoxic T cell (CTL)-mediated antitumor immunity was reflected by ICAM-1-facilitated apoptosis of tumor cells in situ. In contrast, nonfunctional ICAM-1 lacking the N-terminal ligand-binding Ig domain failed to generate antitumor immunity, even in the presence of DMXAA. These studies demonstrate that ICAM-1-stimulated antitumor immunity can overcome tumor-mediated immunosuppression, particularly when employed in combination with an attack on the tumor vasculature. The ligand-binding domain of ICAM-1 is essential for generating antitumor immunity, whereas the cytoplasmic domain and bidirectional activation of tumor signalling pathways are not essential.
I njection of tumors with expression plasmids encoding T cell costimulators such as B7.1, B7.2, intercellular cell adhesion molecule-1 (ICAM-1), and VCAM-1 results in the generation of antitumor cytotoxic T lymphocytes (CTL), whereas in contrast the immune system remains seemingly ignorant of the parental tumor cells. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] The structural requirements for CAM-mediated stimulation of antitumor immunity are unknown. ICAM-1 is an integral membrane glycoprotein possessing an extracellular domain containing five tandem Ig-like domains, a transmembrane domain, and a short cytoplasmic tail. 12 Integrin aLb2 (LFA-1) adheres to the first Ig domain of ICAM-1, 13 whereas aMb2 (Mac-1) expressed on myeloid cells binds to the third Ig domain, 14 indicating that the first Ig domain, at least, should be obligatory for stimulating antitumor immunity. It is now clear that ICAM-1 is not a passive ligand for LFA-1, but is able to transmit signals following ligation that play a role in generating antitumor immunity. ICAM-1 provides sufficient costimulatory signals to induce T cell activation and IL-2 gene expression, but does not protect against anergy induction. 15 It has been proposed to regulate Th2 cytokine production. 16 While B7.1 costimulates both CD4 + and CD8 + subsets of T cells, ICAM-1 is more effective in costimulating CD8 + cells. 17 ICAM-1 acts as a CD28-independent costimulator, and is the dominant, requisite costimulatory molecule for the activation of T cells in the absence of B7/CD28 costimulation. 18 The cytoplasmic domain of ICAM-1 specifically associates with a-actinin, suggesting linkage with the cytoskeleton. 19 Ligation of ICAM-1 induces bidirectional signalling events involving tyrosine phosphorylation of the cell cycle protein cdc2 kinase, inhibition of the production of tumor necrosis factor (TNF)-a, interferon (IFN)-g and IL-1 by T cells, and costimulation of an oxidative burst from mononuclear leukocytes. [20] [21] [22] On B cells, triggering of ICAM-1 plus MHC Class II induces interleukin (IL)-2 receptor expression. 23 Ligation of ICAM-1 on endothelial cells leads to activation of extracellular signal-regulated kinase (Erk)-1, c-jun N-terminal kinase, the AP-1 transcription factor complex, and the Rho signalling pathway; stimulation of Src kinase activity; tyrosine phosphorylation of cortactin, focal adhesion kinase, paxillin, and p130cas; reorganization of the actin cytoskeleton to form stress fibers; and induction of VCAM-1. [24] [25] [26] To identify particular structural domains of ICAM-1 required to generate antitumor immunity, we constructed various ICAM-1 mutants lacking either the ligandbinding or cytoplasmic domains. The mutants were injected intratumorally to determine whether they could generate antitumor immunity in combination with the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA), which has been shown to improve the efficacy of cancer immunotherapy. 27 
Materials and methods

Antibodies and cell lines
The mouse EL-4 thymic lymphoma and COS-7 cells were from the American Type Culture Collection (ATCC, Rockville, MD). The following hybridomas were also obtained from the ATCC: 2E6 (anti-mouse integrin b2 subunit); 53-6.72 (anti-CD8); Gk1.5 (anti-CD4); PK136 (antinatural killer (NK) cell); M17/5.2 (anti-mouse integrin aL subunit); TS2/18.1.2 (anti-human integrin b2 subunit); BE29G1 (anti-mouse ICAM-1); and PY7.2 (antiphosphotyrosine). The HA58 mAb (anti-human ICAM-1) was from Pharmingen, San Diego, CA.
Construction of human ICAM-1 expression plasmids
A full-length human ICAM-1 cDNA clone (HEMBT26) was kindly donated by Dr J Ni, Human Genome Sciences (Rockville, MD), and subcloned into the pCDNA3 expression vector. Overlap PCR was used to generate a deletion mutant lacking Ig-like domains 1 and 2 of ICAM-1 (mut1) (Fig 1a) . In the first step, separate reactions were performed using the primer pairs VFI-1f1 (5 0 -CGAGGGAGCTTCCAGGGGG-3 0 ) and VFI-1r2 5 0 GACACTAGTCTGGGCATTGCCAGGTCCTGG), and VFI-1f3 (5 0 -CCTGGCAATGCCCAGACTAGTGT CCTGCCAG-3 0 ) and VFI-1r4 (5 0 -GGGGGAGAGCA-CATTCACGG-3 0 ), and the plasmid HEMBT26 as template. The PCR products were used as template in a second round of PCR with the primers VFI-1f1 and VFI1r4. The PCR product was subcloned into pCDNA3, and the 800 bp XhoI fragment from HEMBT26 was inserted to generate a wild-type 3 0 -end. The primer pair RWB73 (5 0 -TGTCACTCGAGATCTTGAGG-3 0 ) and RWB74 (5 0 GGAGCTCGAGCCGCTAGCGG TTATAGAGG-3 0 ) were used to PCR a 185 bp product from the HEMBT26 plasmid, which was ligated to a 1.4 kb EcoRI/XhoI wildtype ICAM-1 fragment to generate a cytoplasmic domain-deficient form (mut2), or to the EcoRI/XhoIdigested overlap PCR product to generate mut3 lacking both Ig domains 1 and 2, and the cytoplasmic domain. The integrity of all constructs was verified by DNA sequencing.
Cell adhesion to ICAM-1-transfected COS-7 cells COS-7 cells were stably transfected with full-length ICAM-1 and mut1-3 using lipofectin (Boehringer Mannheim, Mannheim, Germany), and expression levels were analyzed by flow cytometry (Becton Dickinson FACScan, San Jose, CA). Splenic T cells, 90% of which were CD4 + / 8 + T cells, were isolated using nylon wool, and activated for 20 minutes with 50 ng/ml phorbol 12-myristate 13 acetate (PMA; Sigma). They were labelled with 5-(and-6)-carboxyfluorescein diacetate succinimidyl ester (CFDA-SE; Molecular Probes, Eugene, OR) for 30 minutes at room temperature (RT). CFDA-SE-labelled splenic T cells (10 6 ) were overlaid onto methylene blue-stained confluent monolayers of COS-7 transfectants in four chamber slides (Lab Tek Ninc Inc., IL) at 371C for 15 minutes. Unattached cells were removed by washing, and adherent fluorescent lymphocytes were counted.
Experimental tumor model and therapies
Tumors were established by s.c. injection of 2 Â 10 5 EL-4 cells into the left flank of mice, and growth was determined by measuring two perpendicular diameters, as described previously. 6 Animals were euthanized when tumors reached more than 1.0 cm in diameter, in accord with Animal Ethics Approval (University of Auckland). All experiments included five or six mice per treatment group, and each experiment was repeated at least once, unless otherwise indicated. The sodium salt of DMXAA was synthesized in the Auckland Cancer Society Research Centre, University of Auckland. DMXAA was prepared fresh for each experiment, protected from light, and injected i.p. at 25 mg/kg of body weight in a volume of 0.01 ml/g body weight, as described earlier. 27 Expression vectors encoding wild-type ICAM and mut1-3 complexed with liposomes were prepared as described previously. 6 Tumors were injected at multiple sites with 180 ml of DNA (180 mg)/liposome complexes, unless otherwise stated. For combination therapy, DMXAA was administered i.p. 24 hours following injection of ICAM-1 expression plasmids, as described above. Treated mice that remained tumorfree were rechallenged either 26 or 35 days after therapy, by s.c. injection of EL-4 cells (0.1 ml) into the opposing flank (right flank). Methodologies for measurement of antitumor CTL, adoptive transfer of antitumor CTL, depletion of leukocyte subsets, in situ detection of apoptotic cells, and Western blotting of tumor homogenates have been described previously. 6, [27] [28] [29] [30] Immunohistology Tumors were excised 7 days following administration of therapeutic agents and controls, immediately frozen in dry ice, and stored at À701C in isopentane. Sections (10 mm) were mounted on poly l-lysine-coated slides, and endogenous peroxidases blocked in 0.3% H 2 O 2 in methanol. Sections were incubated with HA58 mAb, and developed with the ABC Elite (rat IgG) kit (Vector Laboratories, Burlingame, CA), and SIGMA FAST DAB (3, 3 0 -diaminobenzidine tetrahydrochloride) with metal enhancer CoCl 2 tablets; and counter-stained with hematoxylin. As a control, the primary antibody was substituted with rat IgG (Sigma).
Assessment of tumor vascularity
In all, 10-mm frozen tumor sections prepared 7 days after gene transfer were immunostained with the anti-CD31 antibody MEC13.3 (Pharmingen, CA) to visualize total blood vessels, and with an anti-CD105 antibody (PharMingen, San Diego, CA) to identify neovessels. Stained blood vessels were counted from five mice in six blindly chosen random fields (0.155 mm 2 ) at Â 40 magnification. The concentric circles method 31, 32 was used to assess vascularity. To visualize blood vessels open to flow, DiOC7 (Molecular Probes, Eugene, OR) was injected into the tail vein at a concentration of 1.0 mg/kg 1 minute prior to collecting tissues. 33 Flow cytometry analysis of ICAM-1 gene expression COS-7 transfectants were harvested with trypsin, and stained with HA58 mAb and FITC-conjugated goat antirat IgG (Sigma), or with the FITC-labelled isotypematched control IgG2 a mAb 2G5 recognizing human HML-1. ICAM-1 expression was evaluated by flow cytometry (Becton Dickinson FACScan, San Jose, CA).
Statistical analysis
All experiments were repeated at least once, and results expressed as mean values7standard error of the mean (SEM). A Student's t-test was used for evaluating statistical significance.
Results
Adhesive properties of ICAM-1 mutants
To examine the adhesive properties of ICAM-1 mutants, COS-7 cells were engineered to express wild-type human ICAM-1 and mutated forms mut1-3 (Fig 1a) , and subjected to a heterotypic cell adhesion assay with splenic T cells. Transfectants expressed similar levels of each ICAM-1 variant at the cell surface, as detected by flow cytometry (Fig 1b) . Fluorescent PMA-activated mouse splenic T cells (Fig 1c) displayed significant (Po.001) binding to COS-7 cells transfected with full-length human ICAM-1 and mut2, compared to cells expressing mut1 and 3 and untransfected controls. Cell binding was blocked with mAbs against either ICAM-1 on the transfectants or LFA-1 on the T cells, indicating that mouse LFA-1 binds across species to human ICAM-1. The binding of T cells to mut1 and 3 transfectants was equivalent to background binding to wild-type COS cells, and COS cells transfected with empty plasmid. That mouse aLb2 binds across species to human ICAM-1 was confirmed by the demonstration that mouse splenic T cells bound glass slides coated with recombinant soluble human ICAM-1-Fc in an aLb2-dependent fashion (data not shown). These results demonstrate that human ICAM-1 is active in a mouse system, and that the Nterminal ligand-binding domain of ICAM-1 is required to support leukocyte adhesion, whereas the cytoplasmic domain is dispensible.
Intratumoral injection of a plasmid encoding xenogeneic ICAM-1 inhibits tumor growth
Injection of 60 mg of wild-type ICAM-1 and mut1-3 expression plasmids into EL-4 tumors 0.4 cm in diameter led to detectable levels of plasmid expression, as measured by immunohistochemistical staining of tumor sections (Fig 2a) , and Western blot analysis of tumor cell lysates (Fig 2b) with the anti-ICAM mAb HA58. We have previously shown that EL-4 tumors are composed almost entirely of tumor cells. 30 Figure 2a reveals that at least 90% of cells within the tumor expressed the injected plasmid. Surprisingly, whereas endogenous mouse ICAM-1 was readily detectable in parental EL-4 cells in culture (Fig 2b, lane 7) , it was not detected in single-cell suspensions obtained from EL-4 tumors (Fig 2b, lanes 5  and 6) , suggesting its expression is downregulated in tumors in situ. Injection of varying amounts (60, 120, and 180 mg) of wild-type ICAM-1 plasmid into EL-4 tumors of 0.4-0.5 cm diameter failed to eradicate tumors, but nevertheless significantly (Po.001 at day 35) slowed their growth (Fig 2c) . Inhibition of tumor growth was dependent on gene dosage, with maximal inhibition being achieved with the highest plasmid dosage (180 mg DNA). There was no significant difference in the growth rate of ICAM-1 transfectants in vitro compared to parental EL-4 cells (data not shown), suggesting the plasmids do not inhibit tumor growth per se.
ICAM-1 gene therapy is enhanced by an attack on the tumor vasculature
To determine whether ICAM-1-stimulated antitumor immunity could be enhanced by antivascular therapy, as described previously for B7.1 immunotherapy, 27-29 the antivascular drug DMXAA was administered i.p. 24 hours after intratumoral injection of wild-type ICAM-1 expression plasmid. The effects of DMXAA on tumor vascularity were evaluated using DiOC7, anti-CD31, and anti-CD105 mAb staining 7 days after gene transfer of ICAM-1 and systemic treatment with DMXAA. As shown in Table 1 , DMXAA-treated tumors had a 70-80% increase in the median distance to the nearest DiOC7 perfused, or CD31-and CD105-stained vessel compared with saline or empty vector controls (Po.05). There was also a 65-83% reduction in the numbers of CD31-(Po.05) and CD105-(Po.001) stained, and DiOC7 perfused (Po.001) vessels. Combinational therapy with the ICAM-1 plasmid followed by administration of DMXAA did not further reduce tumor vascularity above that achieved with DMXAA alone. All tumors treated with the ICAM-1 plasmid-DMXAA combination initially regressed completely irrespective of plasmid dosage; however, tumors treated with 60 and 120 mg of ICAM-1 plasmid began to regrow after 2 weeks (Fig 2d) . Tumors receiving the highest dosage of 180 mg ICAM-1 DNA did not regrow, and a challenge with 2 Â 10 5 parental EL-4 
Effectiveness of ICAM-1 mutants in enhancing antitumor immunity
Since antivascular attack augments ICAM-1 immunogene therapy, it was employed to examine the antitumor activities of mut1-3. Injection of 180 mg of mut2 plasmid into EL-4 tumors of 0.4-0.5 cm diameter followed by i.p. administration of DMXAA led to complete tumor rejection, as achieved with full-length ICAM-1 (Fig 3a) . Mice remained tumor-free for the 2 months they were monitored. In contrast, intratumoral injection of mut1 and 3 plasmids failed to cause tumor rejection in combination with DMXAA, and insignificantly (P4.05) retarded tumor growth compared to that achieved with DMXAA alone (Fig 3b) . These results demonstrate that the cytoplasmic domain of ICAM-1 is not required to stimulate antitumor immunity, whereas the N-terminal ligand-binding domain is essential.
Effectiveness of ICAM-1 mutants in generating antitumor CTL
Splenocytes were harvested from ICAM-1 and DMXAAtreated mice 28 days following plasmid injection to Tumor blood vessels in sections from mice treated as indicated were stained with the anti-CD31 or anti-CD105 mAbs, or DiOC7 perfused, and counted in blindly chosen random fields to record mean vessel density per surface area (0.155 mm Requirements for ICAM-1 immunogene therapy JR Kanwar et al measure the generation of antitumor CTL. Antitumor CTL activity was significantly (Po.001) augmented in animals injected with either wild-type ICAM-1 or mut2 in combination with DMXAA treatment, compared to those injected with empty plasmid (Fig 4a) . In contrast, CTL activity generated in response to mut1 and 3 in combination with DMXAA treatment was only slightly enhanced (Po.05) above that obtained with empty plasmid or DMXAA monotherapy. Splenocytes (2 Â 10 8 ) from mice cured by either wild-type ICAM-1 or mut2-therapy in combination with DMXAA were injected i.p. into recipient mice bearing 0.4-0.5 cm diameter tumors. Transfer of the latter antitumor splenocytes led to significant (Po.001) tumor regression, compared to adoptive transfer of splenocytes from mice injected with empty plasmid (Fig 4b) . As expected, splenocytes from mice treated with DMXAA either alone, or in combination with mut1 and 3 afforded no significant (P4.05) protection, and tumors grew unchecked.
EL-4 lymphoma cells are immunosuppressive
A total of 40% (4/10) of mice whose tumors regressed completely after combination therapy with mut2 and DMXAA developed tumors at both the challenge site as well as the primary tumor site, following a challenge with 2 Â 10 5 parental EL-4 cells (Fig 3a) . Since unchallenged mice did not develop tumors, the secondary challenge appears to impair systemic antitumor immunity, as described previously. 6 To demonstrate that EL-4 cells are immunosuppressive, splenic CTL activity was exam- 
Composition of the leukocyte effector cell population responsible for antitumor immunity
In vivo antibody depletion of CD4 + and CD8 + T cells and NK cells revealed that tumor rejection in response to injection of either wild-type ICAM-1 or mut2 expression plasmids in combination with DMXAA was largely dependent on CD8 + T and NK cells, whereas CD4 + T cells had a negligible role to play (Table 2) . Thus depletion of CD8 + T and NK cells inhibited antitumor immunity, and resulted in tumor growth. Simultaneous depletion of CD8 + T and NK cells led to very rapid tumor growth. In accord, immunostaining of tumor sections 4 days after gene transfer of ICAM-1 or mut2 in combination with DMXAA revealed infiltrates of CD8 + T and NK cells, and lesser numbers of CD4 + T cells (data not shown). Since mut1 or 3 plasmids only weakly inhibited tumor growth, and mut1 or 3-treated tumors contained low numbers of CD4 + and CD8 + T cells and NK cells, the compositions of the leukocyte effector populations responsible for their activity were not examined.
Intratumoral injection of either ICAM-1 or mut2 plasmids causes programmed cell death of tumor cells in combination with DMXAA Tumor sections were subjected to TUNEL staining to detect tumor cell apoptosis. Significantly (Po.001) large numbers of apoptotic cells could be observed in tumor sections prepared 7 days following treatment with DMXAA in combination with intratumoral injection of either ICAM-1 or mut2 expression plasmids (Fig 5a) , as quantified in Figure 5b . In contrast, apoptotic cells were sparse in tumors injected with either mut1 or 3 expression plasmids in combination with DMXAA, or in tumors injected with empty plasmid, or following DMXAA monotherapy (Fig 5a and b) . In confirmation, EL-4 cells extracted from tumors expressing either wild-type ICAM-1 or mut2 were efficiently (Po.001) killed by splenocytes from wild-type ICAM-1-DMXAA-treated mice, suggesting that ICAM-1 and mut2 facilitate tumor cell lysis (data not shown). In contrast, EL-4 cells expressing mut1 and 3 were poorly (P4.05) lysed, as were parental EL-4 cells.
Discussion
Here we report, in accord with previous findings, 6 that overexpression of exogenous ICAM-1 by intratumoral injection of xenogeneic ICAM-1 expression plasmids is effective in harnessing an immune response capable of eradicating immunosuppressive EL-4 tumors, in combination with an attack on the tumor vasculature. That ICAM-1 was expressed in EL-4 cells in culture, but not in EL-4 tumors in situ, suggests that downregulation of T cell costimulatory CAMs may be one mechanism by which tumors are rendered less immunogenic. We have employed a xenogeneic form of ICAM-1 here to induce antitumor immunity as xenogeneic forms of T cell costimulators appear to be more effective, and have wider utility. Thus, Wei et al 34 demonstrated that xenogeneic (human) ICAM-1 gene transfer suppresses tumorigenicity and generates protective immunity in rats, whereas tumorigenicity was not significantly reduced when the rat ICAM-1 gene was overexpressed in rat tumor cell lines. They argued that systemic antitumor Mice were injected 7 days before plasmid injection and every alternate day for the duration of the experiment with the mAbs, as indicated. Each value represents the mean difference in tumor size, in centimeters, from days 0 to 21 for leukocyte-type depletion versus no depletion (no mAb) from five mice. P-values refer to the comparison of change in tumor size from days 0 to 21 for leukocyte-type depletion versus no depletion. Data are not included for mut1 and mut3, as these plasmids are not effective at stimulating antitumor immunity.
w Data comparing differences in tumor growth resulting from each leukocyte-type depletion versus no depletion were analyzed using contrasts in a mixed linear model analysis to calculate the significance of values between the antibody-treated group and no mAb(s)-treated group. Pvalues refer to the comparison of change in tumor size from days 0 to 21 for leukocyte-type depletion versus no depletion. The mechanism by which different T cell costimulatory CAMs induce antitumor immunity is unknown. The extracellular domain of CAMs may be important for costimulating responding T cells, or for facilitating lysis of tumor cells by antitumor CTL by assisting in the formation of cell to cell contacts. In agreement with previous results, we found that overexpressed ICAM-1 renders tumor cells more susceptible to killing by antitumor CTL. 6, 35, 36 As expected, extracellular-domaindeficient forms of ICAM-1 (mut1 and 3) did not support cell adhesion, or facilitate tumor cell lysis, or generate effective numbers of antitumor CTL, and consequently did not generate antitumor immunity in combination with DMXAA treatment, which suppresses blood supply to the tumor by reducing tumor vascularity.
The cytoplasmic domain of ICAM-1 mediates an array of signalling events in T and B cells, and endothelial cells; however, a physiologic role for the cytoplasmic domain of ICAM-1 has never been previously examined. B7.1 devoid of its tail cannot normally stimulate T cell proliferation, despite the fact that it can still bind CD28, suggesting that regions within its cytoplasmic tail regulate its costimulatory function. 37 In the present study, we have demonstrated that a cytoplasmic domain-deficient form of ICAM-1 (mut2) transfected into COS-7 cells supports the binding of mouse splenocytes in an LFA-1-dependent fashion, indicating that the cytoplasmic tail is dispensible for receptor binding. Further, DMXAA in combination with the highest dose of mut2 (180 mg) caused complete eradication of tumors, and generated a systemic immune response that protected 60% of mice against a challenge of parental tumor cells. In accord, mut2 facilitated tumor cell lysis both in vitro and in vivo, and generated significant antitumor CTL activity. Antitumor immunity generated by either wild-type ICAM-1 or mut2 immunogene therapy in combination with DMXAA was mediated largely by CD8 + T cells and NK cells. The involvement of NK cells is in accord with the fact that tumor regression was almost immediate, and that ICAM-1 serves as an NK cell receptor. 38 DMXAA induces a variety of bioactive molecules that are effectors of the innate immune response, including TNF-a, interferons, and IP-10, some of which are responsible for DMXAA-mediated hemorrhagic necrosis of tumors. 39 There is strong evidence that TNF-a induces tumor vasculature collapse, in combination with IFN-g. 27, [40] [41] [42] DMXAA may potentiate ICAM-1 immunogene therapy by starving tumors of a blood supply and thereby inhibiting tumor cell growth, and thus preventing the outgrowth of escape variants; by enhancing the innate immune response, and rendering tumors susceptible to NK cell attack; and by rendering the tumor accessible to T cells as the tumor begins to disintegrate.
In summary, while we cannot exclude the possibility that the antitumor activity of xenogeneic ICAM-1 is due, in part, to the ''foreignness'' of the two N-terminal Ig domains, which share 57% amino acid identity with the mouse homologue, it seems more likely that its activity stems from the ability to costimulate CD8 + T cells, to serve as an NK receptor, and to facilitate tumor cell lysis by antitumor CTL. In considering ICAM-1 as a therapeutic agent for cancer immunotherapy, the ligandbinding domain of ICAM-1 is essential for generating antitumor immunity, whereas the cytoplasmic domain and bidirectional activation of tumor signalling pathways are not required. Finally, we have demonstrated that antivascular therapy can potentiate the antitumor activities of different T cell costimulators, now including ICAM-1. This unique combination of therapeutic modalities will need to be tested against a number of different tumor types in different animal models of cancer, incorporating systemic approaches to stimulate antitumor immunity, in order to assess its general clinical utility.
